Hypogammaglobulinemia due to CAR T-cell therapy.
作者信息
Doan Andrew, Pulsipher Michael A
机构信息
Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, California.
出版信息
Pediatr Blood Cancer. 2018 Apr;65(4). doi: 10.1002/pbc.26914. Epub 2017 Dec 12.
Abstract
摘要
相似文献
1
Hypogammaglobulinemia due to CAR T-cell therapy.嵌合抗原受体T细胞疗法所致低丙种球蛋白血症
Pediatr Blood Cancer. 2018 Apr;65(4). doi: 10.1002/pbc.26914. Epub 2017 Dec 12.
2
CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy.CAR-T-外加一份 IgG，可以吗？-接受 CAR-T 细胞治疗的患者的免疫球蛋白替代治疗。
Blood Rev. 2019 Nov;38:100596. doi: 10.1016/j.blre.2019.100596. Epub 2019 Aug 7.
3
Swollen uvula in an 18-year-old man with hypogammaglobulinemia.一名患有低丙种球蛋白血症的18岁男性出现悬雍垂肿胀。
Ann Allergy Asthma Immunol. 2004 Nov;93(5):417-24. doi: 10.1016/S1081-1206(10)61407-X.
4
Hypogammaglobulinemia due to abnormal suppressor T-cell activity in Crohn's disease.克罗恩病中因抑制性T细胞活性异常导致的低丙种球蛋白血症。
Gastroenterology. 1984 Mar;86(3):569-76.
5
Coccidioidomycosis, immunoglobulin deficiency: safety challenges with CAR T cells therapy for relapsed lymphoma.球孢子菌病、免疫球蛋白缺乏：CAR T细胞疗法治疗复发性淋巴瘤的安全性挑战。
Immunotherapy. 2017 Oct;9(13):1061-1066. doi: 10.2217/imt-2017-0070.
6
[Not Available].[无可用内容]
Bull Cancer. 2018 Dec;105 Suppl 2:S158-S167. doi: 10.1016/S0007-4551(19)30046-3.
7
Relapses After CAR-T Therapy.CAR-T疗法后的复发
JAMA. 2018 Nov 13;320(18):1850. doi: 10.1001/jama.2018.17585.
8
Adult Survivorship: Considerations Following CAR T-Cell Therapy.成人幸存者：CAR-T细胞治疗后的注意事项
Clin J Oncol Nurs. 2019 Apr 1;23(2):42-48. doi: 10.1188/19.CJON.S1.42-48.
9
Safer CAR T-Cell Therapy.更安全的嵌合抗原受体T细胞疗法
JAMA. 2019 Jun 11;321(22):2155. doi: 10.1001/jama.2019.7551.
10
Associated Toxicities: Assessment and Management Related to CAR T-Cell Therapy.相关毒性：与嵌合抗原受体T细胞疗法相关的评估与管理
Clin J Oncol Nurs. 2019 Apr 1;23(2):13-19. doi: 10.1188/19.CJON.S1.13-19.
引用本文的文献
1
[Reactivation of cytomegalovirus and its influencing factors in patients with B-lymphocyte malignancy after CAR-T cell therapy].[CAR-T细胞治疗后B淋巴细胞恶性肿瘤患者巨细胞病毒再激活及其影响因素]
Zhonghua Xue Ye Xue Za Zhi. 2024 Nov 14;45(11):1005-1009. doi: 10.3760/cma.j.cn121090-20240703-00249.
2
Association of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality.靶向CD19的嵌合抗原受体（CAR）T细胞疗法与低丙种球蛋白血症、感染及死亡率的关联。
J Allergy Clin Immunol. 2025 Feb;155(2):605-615. doi: 10.1016/j.jaci.2024.10.021. Epub 2024 Nov 4.
3
Comparing the Differences in Adverse Events among Chimeric Antigen Receptor T-Cell Therapies: A Real-World Pharmacovigilance Study.嵌合抗原受体T细胞疗法不良事件的差异比较：一项真实世界药物警戒研究
Pharmaceuticals (Basel). 2024 Aug 5;17(8):1025. doi: 10.3390/ph17081025.
4
Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia.接受CD19+CD22嵌合抗原受体T细胞疗法治疗复发/难治性B淋巴细胞白血病的儿科患者的感染性并发症
Clin Exp Med. 2024 Apr 25;24(1):87. doi: 10.1007/s10238-024-01339-7.
5
International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update.国际移植和细胞治疗长期幸存者的筛查和预防建议：2023 年更新版。
Bone Marrow Transplant. 2024 Jun;59(6):717-741. doi: 10.1038/s41409-023-02190-2. Epub 2024 Feb 27.
6
International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.国际移植和细胞治疗长期幸存者筛查和预防建议：2023 年更新版。
Transplant Cell Ther. 2024 Apr;30(4):349-385. doi: 10.1016/j.jtct.2023.12.001. Epub 2024 Feb 27.
7
The Mechanisms of Altered Blood-Brain Barrier Permeability in CD19 CAR T-Cell Recipients.CD19 CAR T 细胞受者血脑屏障通透性改变的机制。
Int J Mol Sci. 2024 Jan 4;25(1):644. doi: 10.3390/ijms25010644.
8
CAR T cells for treating autoimmune diseases.嵌合抗原受体 T 细胞治疗自身免疫性疾病。
RMD Open. 2023 Nov 23;9(4):e002907. doi: 10.1136/rmdopen-2022-002907.
9
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.血液系统恶性肿瘤的免疫治疗：成就、挑战与未来前景。
Signal Transduct Target Ther. 2023 Aug 18;8(1):306. doi: 10.1038/s41392-023-01521-5.
10
Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond.急性淋巴细胞白血病免疫治疗：现状、未来及展望。
Cancers (Basel). 2023 Jun 26;15(13):3346. doi: 10.3390/cancers15133346.
本文引用的文献
1
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.嵌合抗原受体T细胞在复发难治性慢性淋巴细胞白血病中持续存在并诱导持续缓解。
Sci Transl Med. 2015 Sep 2;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.
2
Chimeric antigen receptor T cells for sustained remissions in leukemia.用于白血病持续缓解的嵌合抗原受体T细胞。
N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.
3
Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes.利妥昔单抗治疗后的低丙种球蛋白血症：发生率和结局。
QJM. 2014 Oct;107(10):821-8. doi: 10.1093/qjmed/hcu094. Epub 2014 Apr 28.
4
The basic principles of chimeric antigen receptor design.嵌合抗原受体设计的基本原则。
Cancer Discov. 2013 Apr;3(4):388-98. doi: 10.1158/2159-8290.CD-12-0548. Epub 2013 Apr 2.
5
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.嵌合抗原受体修饰 T 细胞抗 CD19 治疗的临床试验中，B 细胞耗竭和恶性肿瘤缓解，以及细胞因子相关毒性。
Blood. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8.
6
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.自体 T 细胞经基因工程改造后识别 CD19，用于治疗患者，可消除 B 细胞系细胞并使淋巴瘤消退。
Blood. 2010 Nov 18;116(20):4099-102. doi: 10.1182/blood-2010-04-281931. Epub 2010 Jul 28.
7
Immunoglobulin replacement therapy in children.儿童免疫球蛋白替代疗法
Immunol Allergy Clin North Am. 2008 Nov;28(4):833-49, ix. doi: 10.1016/j.iac.2008.07.001.
8
Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin.皮下注射免疫球蛋白输注作为静脉注射免疫球蛋白的替代方法。
J Allergy Clin Immunol. 2003 Sep;112(3):630-3. doi: 10.1016/s0091-6749(03)01781-0.
9
Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients.儿童无丙种球蛋白血症的早期及长期静脉注射免疫球蛋白替代疗法：31例患者的回顾性调查
J Pediatr. 1999 May;134(5):589-96. doi: 10.1016/s0022-3476(99)70246-5.
Zotero 插件